2-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)(methyl)amino) acetic acid | 1203946-09-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)(methyl)amino) acetic acid
• 英文别名: 2-[2-[Bis(pyridin-2-ylmethyl)amino]ethyl-methylamino]acetic acid；2-[2-[bis(pyridin-2-ylmethyl)amino]ethyl-methylamino]acetic acid
• CAS: 1203946-09-1
• 化学式: C₁₇H₂₂N₄O₂
• 分子量: 314.387
• InChiKey: RRQAKPHRGSCWRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)(methyl)amino) acetic acid 、 N-甲基-D-葡胺 在 N-甲基吗啉 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以43.2%的产率得到2-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)(methyl)amino)-N-methyl-N-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)acetamide
  参考文献：
  名称：

  金属β-内酰胺酶抑制剂锌螯合化合物的合成及生物学评价†

  摘要：

  已经进行了包括具有不同锌亲和力的螯合部分的金属-β-内酰胺酶抑制剂的合成，以及部分受细菌肽序列启发的肽的合成。锌螯合剂的强度使用下列螯合剂来改变，这些螯合剂按结合亲和力的升序排列：二聚烯丙基胺（DPA，三齿），二聚烯丙基-1,2,3-三唑基甲胺（DPTA，四齿）二聚烯丙基乙二胺（DPED，四齿）和三吡啶基乙二胺（TPED，五齿）。选择的肽主要基于细菌肽聚糖前体的C末端的已知序列。对具有NDM-1或VIM-2金属-β-内酰胺酶的临床细菌分离株的生物学评估表明，锌螯合剂的强度与美罗培南活性的恢复之间存在明确的关系。然而，

  DOI：

  10.1039/c8md00578h

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UNIV OSLO

  公开号：WO2018033719A1

  公开（公告）日：2018-02-22

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  该发明提供了一种化合物，用于治疗和/或预防人类或非人哺乳动物体内的细菌感染，所述方法包括将该化合物与β-内酰胺类抗生素（可以同时、分开或顺序地）结合给药，其中所述化合物具有一般式I：（I）（其中：Q是一个亲脂性、选择性结合Zn2+离子的基团，包括至少一个，最好是两个或更多（例如2、3或4个），可选择地取代的不饱和杂环环，例如5或6元杂环环（这些环最好包括至少一个从N、S和O中选择的杂原子，最好是N）；其中任何可选择的取代基可以选择自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个L，可以相同也可以不同，是一个共价键或一个连接基；每个W，可以相同也可以不同，是一个非肽性亲水基团，包括一个或多个羟基；x是1到3之间的整数）或其立体异构体、药学上可接受的盐或前药。
• Two tetranuclear Mn-complexes as biomimetic models of the oxygen evolving complex in Photosystem II. A synthesis, characterisation and reactivity study
  作者：Gustav Berggren、Anders Thapper、Ping Huang、Philipp Kurz、Lars Eriksson、Stenbjörn Styring、Magnus F. Anderlund

  DOI：10.1039/b906175d

  日期：——

  In this work we report the preparation of two metallamacrocyclic tetranuclear manganese(II) complexes, [L14Mn4](ClO4)4 and [L24Mn4](ClO4)4 where L1 and L2 are the anions of the heptadentate ligands 2-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)(methyl)amino)acetic acid and 2-(benzyl(2-(bis(pyridin-2-ylmethyl)amino)ethyl)amino)acetic acid), respectively. The complexes have been fully characterized by ESI-MS

  在这项工作中，我们报告了两种金属镧环四核锰（II）配合物[ L1 4 Mn 4 ]（ClO 4）4和[ L2 4 Mn 4 ]（ClO 4）4的制备，其中L1和L2是七齿的阴离子配体 2-（（2-（双（吡啶-2-基甲基）氨基）乙基）（甲基）氨基）乙酸和2-（苄基（2-（双（吡啶-2-基甲基）氨基）乙基）氨基）乙酸）。配合物已被充分表征为电喷雾质谱， 元素分析， 单晶X射线衍射，磁化率和 EPR光谱。已经进行了电化学反应以及与不同化学氧化还原试剂的反应，并且可逆的两个电子氧化作用每锰离子已被鉴定。[ L1 4 Mn 4 ]（ClO 4）4与酮 或铈（IV）会导致氧气的释放，这使该系统对于在Photosystem II中寻找氧气释放复合物的功能模拟物的未来研究很感兴趣。
• Compounds
  申请人：UNIVERSITETET I OSLO

  公开号：US10961223B2

  公开（公告）日：2021-03-30

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  本发明提供了用于治疗和/或预防人类或非人类哺乳动物细菌感染的方法的化合物，所述方法包括将所述化合物与β-内酰胺类抗生素（同时、分别或依次）联合给药，其中所述化合物具有通式I： (I) (其中：Q 是对 Zn2+ 离子有选择性的亲脂性锌螯合基团，它包括至少一个，最好是两个或更多 （例如 2、3 或 4 个）任选取代的不饱和杂环，例如5或6元杂环（此类环最好包括至少一个选自N、S和O的杂原子，最好是N）；其中任选取代基可选自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个 L（可以相同或不同）是共价键或连接体；每个 W（可以相同或不同）是非肽亲水基团，包括一个或多个羟基；以及 x 是 1 至 3 的整数）或其立体异构体、药学上可接受的盐或原药。
• ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION
  申请人：Universitetet I Oslo

  公开号：EP3497095B1

  公开（公告）日：2021-07-14
• COMPOUNDS
  申请人：UNIVERSITETET I OSLO

  公开号：US20190284167A1

  公开（公告）日：2019-09-19

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn 2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.